Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction
of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer
The emergence of immune checkpoint inhibitors (ICIs) has dramatically changed the therapeutic outlook for patients with non-small cell lung cancer (NSCLC). Preoperative neoadjuvant immunotherapy has been paid more and more attention as an effective and safe treatment. Neoadjuvant immune therapy, however, the relevant research started late, relatively few research results and mainly focused on the small sample size of phase I and II studies, treatment itself exists many places it is not clear, also in benefit population screening, the respect such as the choice of treatment and curative effect prediction has not yet reached...
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer
Conclusion At present, there is no standard treatment specification for BRAF non-V600E mutation targeted therapy. The challenge lies in the heterogeneous mutation of BRAF gene. Different mutation types respond differently to targeted therapy. In addtion, real-world research evidence is scarce, so it is necessary to carry out further large-sample high-quality research to provide reference for clinical practice.
DOI: 10.3779/j.issn.1009-3419.2021.101.51 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
PRKCDBP Methylation is a Potential and Promising Candidate Biomarker for Non-small Cell Lung Cancer
Conclusion: PRKCDBP methylation is a potential and promising candidate biomarker for non-small cell lung cancer. DOI: 10.3779/j.issn.1009-3419.2022.102.03 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - February 20, 2022 Category: Cancer & Oncology Source Type: research
Application of CT-guided Localization with Medical Glue for Single and Two or More Small Pulmonary Nodules before Video-assisted Thoracic Surgery
Conclusion Compared with localization of single lung nodule, unilateral CT-guided medical glue localization for multiple pulmonary nodules before VATS is also feasible and accuracy, it is worthy of clinical application. But the higher rate of pneumothorax should be paid attention to.
DOI: 10.3779/j.issn.1009-3419.2021.102.52 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - January 26, 2022 Category: Cancer & Oncology Source Type: research
A Case Report of AFP-producing Primary Lung Squamous Cell Carcinoma
with Significant Therapeutic Effect
Conclusion The AFP-producing lung squamous carcinoma patient had a good response to anlotinib and immunotherapy in the case report, which may provide some guidances for the clinical practice and the research on AFP-producing lung squamous carcinoma.
DO I: 10.3779/j.issn.1009-3419.2021.101.50 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review
We report 2 cases of diabetes mellitus associated with ICIs. Literature review was conducted and we discussed the clinical presentation, potential mechanisms and suggestions for optimal management. Two patients were both elderly women, case 1 had increased blood glucose after 7 months of using Durvalumab, and cases 2 had diabetic ketoacidosis after 6 weeks of using Pembrolizumab. Both patients were administered exogenous insulin to control blood glucose. Case 1 has been treated with Durvalumab until now and case 2 discontinued using of Pembrolizumab. HLA genotypes and other factors may explain the risk factors of diabetes ...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress on Spread Through Air Spaces of Lung Cancer
The concept of spread through air spaces (STAS) was first proposed in the World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart (version 2015). STAS is defined as the micropapillary clusters, solid nests or single cells of tumor that exist in the air spaces of the surrounding lung parenchyma beyond the edge of the main tumor. Meanwhile, apart from the traditional invasion modes of lung adenocarcinoma (interstitial, visceral pleura and lym-phovascular invasion), STAS has been identified as the fourth invasion mode of lung adenocarcinoma. In recent years, the research on STAS has been...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer
Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author revi...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Progress of Research on the Relationship between Lung Microbiome and Lung Cancer
The microbiota plays an important role in the biological functions of the human body and is associated with various disease states such as inflammation (gastritis, hepatitis) and cancer (stomach, cervical, liver). The Human Microbiome Project painted a panorama of human microorganisms in its first phase, incorporating body parts such as the nasal cavity, oral cavity, intestine, vagina and skin, while the lungs were considered a sterile environment. However, studies in recent years have confirmed the presence of a rich microbial community in the lung, and the association of this lung microbiota with lung disease has become ...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Advances in the Study of Tumor-associated Macrophages in Lung Cancer
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in China. Therefore, the research on the treatment of lung cancer is also deepening. At present, there are mainly systemic chemotherapy, targeted therapy for positive driver genes, the application of immune checkpoint inhibitors, anti-tumor angiogenesis therapy and the combination of the different treatment methods mentioned above. The use of these regimens has significantly improved the prognosis of most lung cancer patients, but the prognosis of patients with advanced lung cancer remains unsatisfactory. Recently, more and more attention h...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Pattern of Recurrence and Metastasis after Radical Resection of
Non-small Cell Lung Cancer
The rate of recurrence and metastasis of non-small cell lung cancer after radical resection is still very high. The risk factors for recurrence and metastasis have been extensively studied, but the dynamic pattern of postoperative recurrence hazard over time is relatively lacking. The dynamic recurrence hazard rate curve is applied to describe the rate of recurrence at any point time among the “at-risk” patients. In this article, by reviewing the previous literature, the characteristics of the dynamic recurrence and metastasis pattern after radical resection of non-small cell lung cancer and the clinical factors affect...
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Correlation Analysis of the Lung Volume Reduction and the Lung Function Loss
after the Thoracoscopic Lobectomy
Conclusion The decrease of lung tissue volume after lobectomy is the main reason for the decrease of lung function, especially in the left lower lobe. And 3 months after lobectomy can be selected as the evaluation node of residual lung function.
DOI: 10.3779/j.issn.1009-3419.2021.103.15 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Study on the Benefit of Postoperative Exercise Rehabilitation in Patients with
Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease
Conclusion Postoperative exercise rehabilitation tr aining can improve exercise endurance and daily activity ability of patients with lung cancer complicated with COPD and promote postoperative rehabilitation.
DOI: 10.3779/j.issn.1009-3419.2021.102.51 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma
Conclusion Pemetrexed maintenance therapy following initial pemetrexed and platinum chemotherapy improve PFS in patients with MPM, and is well tolerated.
DOI: 10.3779/j.issn.1009-3419.2021.101.48 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research
Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)
Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (ALKi), such as crizotinib, ceritinib, alectinib and ensartinib have been approved in China. However, there was no guidance for the management of ALKi adverse reactions. Therefore, this " Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version) " has been summarized, led by Lung Cancer ...
Source: Chinese Journal of Lung Cancer - December 20, 2021 Category: Cancer & Oncology Source Type: research
